The Role of Monoclonal Antibodies in the Management of Leukemia

Pharmaceuticals

Ali Al-Ameri¹  Mohamad Cherry²  Aref Al-Kali¹ 

[1] Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX 77005, USA;Department of Internal Medicine, Hematology Oncology section, Oklahoma University Health Sciences Center, 700 N.E. 13th Street, Oklahoma City, OK 74103, USA

关键词: monoclonal Abs;    leukemia;    CLL;    AML;    ALL;   

DOI  :  10.3390/ph3103258

来源: mdpi

【 摘 要 】

This article will review the monoclonal antibodies more commonly used in leukemias. In the last three decades, scientists have made considerable progress understanding the structure and the functions of various surface antigens, such as CD20, CD33. The introduction of rituximab, an anti CD20 monoclonal antibody, had a great impact in the treatment of lymphoproliferative disorders. Gemtuzumab, an anti CD 33 conjugated monoclonal antibody has activity in acute mylegenous leukemia (AML). As this field is undergoing a rapid growth, the years will see an increasing use of monoclonal antibodies in hematological malignancies.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.